2022 - Research.com Best Female Scientist Award
Brenda M. Sandmaier mainly focuses on Transplantation, Internal medicine, Hematopoietic stem cell transplantation, Surgery and Oncology. Her Transplantation research is multidisciplinary, incorporating perspectives in Immunosuppression, Immunology, Total body irradiation, Transplantation Conditioning and Fludarabine. Brenda M. Sandmaier combines topics linked to Gastroenterology with her work on Internal medicine.
Her biological study spans a wide range of topics, including Cumulative incidence, Retrospective cohort study, Myelodysplastic syndromes, Survival analysis and Acute leukemia. Her work in Surgery tackles topics such as Comorbidity which are related to areas like Cause of death and Clinical trial. Her research in Oncology intersects with topics in Cancer, Cancer vaccine, Immunotherapy, Stem cell and Lymphoma.
Her scientific interests lie mostly in Transplantation, Internal medicine, Hematopoietic stem cell transplantation, Surgery and Oncology. Her research integrates issues of Immunosuppression, Immunology, Total body irradiation and Fludarabine in her study of Transplantation. Her Internal medicine research includes themes of Gastroenterology and Hematopoietic cell.
The study incorporates disciplines such as Survival rate, Myeloid, Cumulative incidence, Transplantation Conditioning and Survival analysis in addition to Hematopoietic stem cell transplantation. Brenda M. Sandmaier has included themes like Urology and Comorbidity in her Surgery study. The Oncology study combines topics in areas such as Chemotherapy, Minimal residual disease, Myeloid leukemia, Myelodysplastic syndromes and Lymphoma.
Her primary areas of study are Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Fludarabine. Her Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology. Brenda M. Sandmaier is involved in the study of Transplantation that focuses on Graft-versus-host disease in particular.
Her Oncology research incorporates elements of Complete remission, Chemotherapy, Young adult, Minimal residual disease and Lymphoma. In her work, Surgery is strongly intertwined with Univariate analysis, which is a subfield of Hematopoietic stem cell transplantation. Her studies in Fludarabine integrate themes in fields like Radioimmunotherapy, B-cell lymphoma and Sirolimus.
The scientist’s investigation covers issues in Transplantation, Internal medicine, Oncology, Hematopoietic stem cell transplantation and Hazard ratio. Brenda M. Sandmaier combines subjects such as Retrospective cohort study, Cumulative incidence, Total body irradiation, Myeloid leukemia and Fludarabine with her study of Transplantation. Her Internal medicine research incorporates themes from Gastroenterology and Surgery.
She has researched Oncology in several fields, including Hematopoietic cell, Cohort, Young adult, Allogeneic transplantation and Multiple myeloma. Her Hematopoietic stem cell transplantation research is multidisciplinary, relying on both Antibody and Proportional hazards model. Her Hazard ratio research incorporates themes from Survival analysis and Immunology, Cord blood.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.
Mohamed L. Sorror;Michael B. Maris;Michael B. Maris;Rainer Storb;Rainer Storb;Frederic Baron.
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
Leo Luznik;Paul V. O'Donnell;Paul V. O'Donnell;Heather J. Symons;Allen R. Chen.
Biology of Blood and Marrow Transplantation (2008)
Reduced mortality after allogeneic hematopoietic-cell transplantation.
Ted A. Gooley;Jason W. Chien;Jason W. Chien;Steven A. Pergam;Steven A. Pergam;Sangeeta Hingorani;Sangeeta Hingorani.
The New England Journal of Medicine (2010)
Defining the intensity of conditioning regimens: working definitions.
Andrea Bacigalupo;Karen Ballen;Doug Rizzo;Sergio Giralt.
Biology of Blood and Marrow Transplantation (2009)
Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.
Marco Mielcarek;Paul J. Martin;Wendy Leisenring;Mary E. D. Flowers.
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
Dietger Niederwieser;Michael Maris;Judith A. Shizuru;Effie Petersdorf.
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Sergio Giralt;Karen Ballen;Douglas Rizzo;Andreas Bacigalupo.
Biology of Blood and Marrow Transplantation (2009)
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma
David G. Maloney;Arthur J. Molina;Firoozeh Sahebi;Keith E. Stockerl-Goldstein.
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning.
Takahiro Fukuda;Michael Boeckh;Michael Boeckh;Rachel A. Carter;Rachel A. Carter;Brenda M. Sandmaier;Brenda M. Sandmaier.
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Michael B. Maris;Dietger Niederwieser;Brenda M. Sandmaier;Barry Storer.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: